Executive Chairman of the Board, Fu Wei, informed the Company of his intent to purchase up to $5,000,000 of the Company’s American Depository Shares (ADSs)ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that Fu Wei, Executive Chairman of the Board, intends to purchase up to $5,000,000 of the Company’s ADSs in open market transact ...

NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader Opening the first trading session of the New Year marks an excellent beginning to 2026 for NovaBridgeInclusion in the Nasdaq Biotech Index (NBI) enhances NovaBridge’s visibility and emphasizes the Company’s position as an industry leader ROCKVILLE, Md., Dec. 30, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company co ...

Core Insights - NovaBridge Biosciences announced new data from the Phase 1 dosing study of ragistomig, a bispecific 4-1BB X PD-L1 antibody, showing consistent antitumor activity and improved safety profile with a new dosing schedule [1][2][3] Group 1: Study Results - The new Q6W dosing schedule demonstrated a disease control rate (DCR) of 58.8%, comparable to the 64.3% DCR observed with the previous Q2W schedule [7] - Only 5% of patients experienced Grade ≥3 liver function test (LFT) elevations with the Q6W regimen, compared to 40% with the Q2W regimen [13] - The study achieved its objective of extending the therapeutic window, supporting the advancement of ragistomig into combination studies [2][3] Group 2: Immunological Data - The Q6W dosing showed positive immunological data, including expansion of effector memory and CD8+ T cells, indicating durable immune engagement [7][13] - The study reported no cases of cytokine release syndrome (CRS) with either dosing schedule, highlighting the favorable safety profile [7][13] Group 3: Patient Characteristics - The study included 20 heavily pre-treated subjects receiving 3 mg/kg Q6W ragistomig, with 100% previously treated with immuno-oncology therapies [12] - Among the 17 evaluable patients on the Q6W regimen, the objective response rate was 11.8%, while the Q2W regimen had a 28.6% response rate [9] Group 4: Future Directions - The ongoing evaluation of the 5 mg/kg Q6W dosing cohort and future combination studies is anticipated to further assess the efficacy of ragistomig [8]

Core Insights - NovaBridge Biosciences announced new data from the expanded Phase 1 dosing study for ragistomig, a bispecific antibody targeting 4-1BB and PD-L1, to be presented at ESMO-IO 2025 [1][2] - The study successfully extended the therapeutic window for ragistomig, demonstrating strong anti-tumor efficacy and improved tolerability, including enhanced hepatic safety [2][3] - Ragistomig aims to provide new treatment options for patients resistant to checkpoint inhibitors, a significant drug class in cancer therapy [3][5] Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with clinical development [8] - The company is developing a differentiated pipeline, including ragistomig and givastomig, targeting various cancers and conditions [8][9] - Ragistomig is being developed in collaboration with ABL Bio, utilizing advanced bispecific antibody technology to minimize off-tumor toxicity [5][6] Clinical Study Details - The Phase 1 study of ragistomig is ongoing in the U.S. and South Korea, with a primary focus on defining dose-limiting toxicity and adverse event profiles [5][6] - The new dosing schedule, Q6W, has shown promising results in PD-L1 non-responders, balancing safety and sustained efficacy [6][7] - Interim results, including immunological data, are expected to be presented at the upcoming ESMO-IO meeting [6][7]

Core Insights - NovaBridge Biosciences announced the appointment of Dr. Cadmus C. Rich as Chief Medical Officer and Dr. Carlos Quezada-Ruiz as Chairman of the Scientific Advisory Board for its subsidiary Visara, Inc. [1][2][3] Company Developments - The appointments of Dr. Rich and Dr. Quezada-Ruiz highlight Visara's commitment to developing innovative ophthalmic therapies, particularly the VIS-101 program targeting wet age-related macular degeneration (wet AMD) [2][5][12] - Dr. Rich aims to accelerate the development of new ophthalmology treatments and is focused on completing the Phase 2 study of VIS-101 [2][12] - Dr. Quezada-Ruiz brings extensive experience in retinal therapies and emphasizes the need for more durable treatment options for retinal diseases [2][10] Product Pipeline - VIS-101 is a bifunctional biologic targeting VEGF-A and ANG-2, with potential applications in wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO) [5][12][17] - The drug is expected to be Phase 3-ready in 2026, following the completion of its current Phase 2 study [5][12] Leadership Expertise - Dr. Rich has a strong background in ophthalmology and drug development, having previously held leadership roles in various biopharmaceutical companies [4][6][7] - Dr. Quezada-Ruiz has significant experience in the global development of retinal therapies and has held senior positions at major pharmaceutical companies [8][9][10] Strategic Vision - The appointments are part of NovaBridge's strategic transformation into a global biotech platform, showcasing its ability to attract top-tier talent in the industry [3][5] - The company aims to deliver value to shareholders through its innovative "hub-and-spoke" strategy [3]

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in various clinical trial stages [1] - The company has strategic partnerships with industry leaders, enhancing its research and development capabilities [1] Price Target Changes - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00, indicating a shift in analyst sentiment [2][5] - This decline in price target suggests potential influences from recent developments or broader market conditions affecting the biotech sector [2] Investment Considerations - Investors should monitor NovaBridge's ongoing clinical trials and strategic partnerships, as these factors could significantly impact future performance and stock valuation [3][5] - New announcements or updates from NovaBridge may provide further insights into potential stock movements [3] Comparative Analysis - In contrast, IMab has received a positive outlook from analysts, with a price target set at $8, reflecting increased optimism about its earnings prospects [4] - This comparison highlights the importance of analyst ratings and price targets in assessing biotech stocks [4][5]

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in various clinical trial stages [1] - The company has established strategic partnerships with major players in the industry to enhance its research and development efforts [1] Price Target Analysis - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00 over the past month, indicating a more cautious short-term outlook from analysts [2][5] - Despite the recent decrease, the price target has remained stable over the past year, suggesting a consistent long-term view of the company's potential [2] Comparative Analysis with IMab - IMab has been upgraded to a Zacks Rank 2 (Buy), with a new price target of $8 set by analyst Kumaraguru Raja, reflecting increased optimism about its earnings potential [3][5] - The contrasting outlooks for NovaBridge and IMab highlight varied analyst sentiments based on recent developments in the biotech sector [4][5]

Core Insights - NovaBridge Biosciences is focused on developing immuno-oncology agents for cancer treatment, with several projects in clinical trials and strategic partnerships enhancing its capabilities [1] - The consensus price target for NovaBridge's stock has decreased from $7.75 to $7.00 over the past year, indicating a decline in analyst optimism [2][5] - Recent changes in the price target may be influenced by clinical trial developments, strategic partnerships, or broader market conditions affecting the biotech sector [3] Company Overview - NovaBridge is developing promising immuno-oncology agents such as givastomig, uliledlimab, and ragistomig, which are at various clinical trial stages [1] - The company has established strategic partnerships with major players like Ferring International Center SA, Bristol Myers Squibb, ABL Bio, Inc., and TJ Bio [1] Market Comparison - In contrast to NovaBridge, IMab has been upgraded to a Zacks Rank 2 (Buy), with a price target of $8, indicating increased optimism regarding its earnings potential [4] - The differing analyst views on NovaBridge and IMab highlight the varying expectations within the biotech sector [5]

Core Viewpoint - NewBridge Bio has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities acting as joint sponsors [1] Company Overview - NewBridge Bio is a biotechnology platform company established in 2016, focusing on the development of innovative precision immuno-oncology drugs [1] - The core product, Givastomig, is a novel bispecific antibody targeting CLDN18.2 and 4-1BB, applicable for gastric adenocarcinoma, biliary tract cancer, and pancreatic ductal adenocarcinoma [1] Product Development - Givastomig offers broader applicability and precise local immune activation in tumors compared to existing antibodies, potentially reducing systemic side effects [1] - The company has completed Phase I clinical trials for Givastomig and plans to initiate Phase II trials in early 2026 [1] - In addition to Givastomig, NewBridge Bio has three other clinical-stage projects, including uliledlimab, ragistomig, and VIS-101 [1]

Core Viewpoint - New Bridge Bio, established in 2016, is a global biotechnology platform company focused on developing innovative precision immuno-oncology drugs for cancer treatment, utilizing a new business model to enhance its drug pipeline through strategic collaborations and specialized subsidiaries [3][4]. Company Overview - New Bridge Bio primarily develops its proprietary drug, givastomig, a bispecific antibody targeting Claudin18.2 and 4-1BB, which is effective against various gastrointestinal malignancies including gastric, esophageal, and pancreatic cancers [3][4]. - The company aims to leverage its new business model to select and advance high-value therapeutic assets through dedicated subsidiaries, enhancing operational focus and risk management [3]. Product Details - Givastomig is designed to target tumors with low Claudin18.2 expression effectively and activates T-cells specifically at the tumor site, potentially reducing systemic side effects associated with traditional therapies [4]. - The global market for first-line treatments for gastric and esophageal adenocarcinoma (GEA), biliary tract cancer (BTC), and pancreatic ductal adenocarcinoma (PDAC) is projected to grow significantly, with estimates of $8.9 billion, $1.8 billion, and $4.4 billion respectively by 2034 [5]. Clinical Development - New Bridge Bio has completed the Phase I clinical study and plans to initiate a randomized Phase II study in early 2026, having received no objections from the FDA regarding its clinical trial plans for givastomig [5]. - The company has established a pipeline that includes three clinical-stage projects, with two focused on oncology and one in ophthalmology [5]. Financial Performance - For the fiscal year 2023, New Bridge Bio reported total revenues of approximately -$202.12 million, with significant operating losses due to high research and administrative expenses [6]. - The company’s revenue from licensing and collaboration was recorded at $632,000 for 2023, with total expenses amounting to $72.65 million [6].